Literature DB >> 9381338

Delayed diagnosis of malignant tumors missed at laparoscopic cholecystectomy.

W Junger1, W G Junger, J Hutter, K Miller, E Moritz.   

Abstract

BACKGROUND: The aim of this study was to compare the significance of routine examinations prior to laparoscopic cholecystectomy (LC) with intraoperative abdominal investigation. Preoperative evaluation becomes increasingly important when laparoscopic procedures are performed for the removal of gallstones because other intraabdominal diseases may coexist in these patients, mimicking biliary tract disease.
METHODS: Over the last 6 years, we treated 816 patients with symptomatic cholecystolithiasis using LC. Prior to surgery, routine tests such as upper abdominal ultrasonography, chest radiography, and standard laboratory blood tests were carried out.
RESULTS: Despite these routine tests, coexisting colonic cancers escaped detection in four out of 816 cases. This indicates a risk of more "missed pathologies" during the course of laparoscopic operations compared to standard laparotomy.
CONCLUSION: The risk of missing coexisting diseases during laparoscopic operations has to be minimized by placing additional emphasis on careful evaluation of anamnesis. Physical examination and additional laboratory tests--such as analysis of tumor markers and blood in the stool--combined with complete abdominal ultrasonography, gastroscopy, and/or complete colonoscopy should be performed prior to LC.

Entities:  

Mesh:

Year:  1997        PMID: 9381338     DOI: 10.1007/s004649900513

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  2 in total

1.  Abdominal malignancies missed during laparoscopic cholecystectomy.

Authors:  A Wysocki; W Lejman; A Bobrzynski
Journal:  Surg Endosc       Date:  2001-06-12       Impact factor: 4.584

2.  Missed intra-abdominal malignancies after laparoscopic cholecystectomy.

Authors:  Gokhan Icoz; Ozer Makay; Murat Dayangac; Murat Zeytunlu; Murat Kilic; Mustafa Korkut
Journal:  Ann Saudi Med       Date:  2005 Mar-Apr       Impact factor: 1.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.